title: Neuromodulation of the cardiac vagus: comparison of neuropeptide Y and related peptides.
abstract: Neuropeptide Y (NPY), a putative co-transmitter in noradrenergic sympathetic nerves of the cardiovascular system, inhibits the negative chronotropic action of the cardiac vagus. In the present study, peptides related to NPY were tested for potency in producing this effect. In bilaterally vagotomized, anaesthetised dogs, the increase in pulse interval caused by electrical stimulation of the peripheral stump of the right vagus was measured before and after intravenous administration of peptide. The effects of doses of NPY were compared with those of equimolar doses of peptide YY (PYY), and of avian and human pancreatic polypeptides (APP and HPP). PYY inhibited the vagal action more effectively than did NPY. APP and HPP, however, caused no change in strength of vagal action at the doses used. The response to a second injection of NPY, given soon after the injection of APP or HPP, was not significantly different from the original. Thus no evidence was obtained for a competitive inhibition of the action of NPY by either pancreatic polypeptide. A C-terminal hexapeptide fragment of human pancreatic polypeptide was also tested. Like APP and HPP, it neither inhibited the cardiac vagus nor blocked the action of NPY. The order of potency obtained here (PYY greater than NPY much greater than APP, HPP, CFPP) can be expected to be of use in efforts to distinguish the active site(s) of the NPY molecule, and to characterise the receptors involved in these modulatory effects.
authors.forename: M J
authors.initials: MJ
authors.lastname: Kilborn
authors.forename: E K
authors.initials: EK
authors.lastname: Potter
authors.forename: D I
authors.initials: DI
authors.lastname: McCloskey
mesh_terms: D000818:Animals; D001794:Blood Pressure / Q000187:drug effects*; D002417:Cattle; D004285:Dogs; D005260:Female; D006329:Heart Conduction System / Q000187:drug effects*; D008297:Male; D009419:Nerve Tissue Proteins / Q000494:pharmacology*; D009478:Neuropeptide Y; D018377:Neurotransmitter Agents / Q000494:pharmacology*; D010191:Pancreatic Polypeptide / Q000494:pharmacology; D019894:Peptide YY; D010455:Peptides / Q000494:pharmacology; D011433:Propranolol / Q000494:pharmacology; D011674:Pulse / Q000187:drug effects*; D011943:Receptors, Adrenergic, beta / Q000187:drug effects; D013045:Species Specificity; D013329:Structure-Activity Relationship; D014628:Vagotomy
chemical_list: D009419:Nerve Tissue Proteins; D009478:Neuropeptide Y; D018377:Neurotransmitter Agents; D010455:Peptides; D011943:Receptors, Adrenergic, beta; D019894:Peptide YY; D010191:Pancreatic Polypeptide; D011433:Propranolol